CROI 2005: Index of Coverage

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

Key Links:

By Topic:

Search:

Complications of HIV/HAART

Odds and Ends From CROI 2005: CD4+ Testing, Enfuvirtide Site Reactions, Erectile Dysfunction and Cancers (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Body Shape, Lipids and Cardiovascular Disease at CROI (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Severity and Rate of Abacavir Hypersensitivity Reactions Higher Than Previously Believed (February 23, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Developing World

Uganda's Decline in HIV/AIDS Prevalence Attributed to Increased Condom Use, Early Death From AIDS, Study Says (February 24, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Drug Resistance

K65R Mutation Revealed in 4 Non-Responders to Abacavir + Lamivudine + Tenofovir Failed Regimen -- Significance Unclear (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Update on Salvage Therapy for HIV-Infected Patients (February 25, 2005)
A detailed review of recent research related to the treatment of patients with multi-drug resistance, including an examination of developing drugs.
To read PDF, click here
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Epidemiology

HIV Treatment: 2 Million Years of Life Saved in U.S. (March 1, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
First Human HTLV Cases Discovered in Cameroon (February 28, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
HIV Prevalence Among U.S. Blacks Was 2.14% in 2001, CDC Says (February 28, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
In New York City, Unsafe Sex More Likely Among HIV-Infected Women Than HIV-Infected Gay or Heterosexual Men (February 28, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Researchers Still Divided Over Significance of New York City Case of Rare, Drug-Resistant HIV Strain (February 25, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Probable Acquisition of Multi-Drug-Resistant HIV in Man With Subsequent Rapid HIV Disease Progression: Reality and Reaction (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

New Antiretrovirals

Ritonavir-Boosted Tipranavir Update at CROI 2005 (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
TMC-114 Sets a New Standard in Salvage Therapy Trials (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Update on Salvage Therapy for HIV-Infected Patients (February 25, 2005)
A detailed review of recent research related to the treatment of patients with multi-drug resistance, including an examination of developing drugs.
To read PDF, click here
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Safety and Pharmacokinetic Data for 640385, a New Protease Inhibitor in Development (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Antiviral Benefits of 873140, a CCR5 Antagonist (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Pathogenesis

Scientists Discover a Key to How AIDS Virus Attacks the Body (February 24, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention

Pharmacokinetics

CNS Penetration of Antiretroviral Agents May Not Be Essential for Prevention of AIDS-Related Dementia (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
New Research Explores Potential Value of Therapeutic Drug Monitoring (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Relevance of Host Genotype on Nevirapine Drug Levels (February 23, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Prevention

Microbicide Pilot Study Shows Promise in Women (March 9, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Treatment-Naive Patients

Acute HIV Infection: A Unique Opportunity to Intervene (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Multi-National Trial Confirms Superiority of 3-Drug Regimen Containing Efavirenz for the Treatment Naive (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
EuroSIDA Study Confirms Ability of Most HAART Regimens to Decrease Rates of Illness and Death (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Meta-Analysis of Triple-Combination Therapy in Treatment-Naive Patients (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Mortality Unaffected by Initial HAART Regimen Choice (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Treatment Switching/Simplification

Comparing a Treatment Interruption With or Without Interleukin-2 in Delaying a Falling CD4+ Cell Count (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Dual NRTI Plus Efavirenz Regimen Superior to Boosted PI Plus Efavirenz (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Strategies for Switching and Simplifying Antiretroviral Treatment in HIV-Infected Patients: Part I: Research Update (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Strategies for Switching and Simplifying Antiretroviral Treatment in HIV-Infected Patients: Part II: Case Studies (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Women and HIV/HAART

Combination Therapy Might Be Better Choice Than Nevirapine Alone to Prevent Vertical HIV Transmission, Researchers Say (February 25, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Problems With Drug Resistance Persist in the Prevention of Mother-to-Child Transmission in the Developing World (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Cervical and Anal Dysplasia in Women, Not Gone and Not Forgotten (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Gender and Age Differences in HIV Care and Treatment? Two Studies Note Few Differences (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.